What it's for (Indications)
- Clomiphene citrate, exemplified by Ovafin 50mg, is primarily indicated for the treatment of ovulatory dysfunction in women desiring pregnancy.
- It is prescribed for anovulatory or oligo-ovulatory women, including those with polycystic ovary syndrome (PCOS), who wish to conceive and in whom other causes of infertility have been excluded.
- Its utility lies in stimulating ovulation in patients where there is no evidence of primary ovarian or pituitary failure.
- Effective use requires a functioning hypothalamic-pituitary-ovarian axis and adequate estrogen levels.
- Before initiating therapy, a thorough evaluation of the infertile couple is essential to rule out other causes of infertility that would not be addressed by clomiphene, ensuring appropriate patient selection.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended starting dose for clomiphene (e.g., Ovafin 50mg) is 50 mg administered orally once daily for 5 days. Treatment should commence on or about the 5th day of the menstrual cycle, or at any time in anovulatory patients without regular cyclic bleeding. If ovulation does not occur after the first course of therapy, a second course of 100 mg daily for 5 days may be initiated, typically at least 30 days after the previous course. Doses above 100 mg daily for 5 days are not recommended due to limited evidence of increased efficacy and a higher incidence of side effects. Most patients who will ovulate will do so on the 50 mg or 100 mg regimen. Prolonged use beyond six treatment cycles is generally discouraged as the likelihood of success diminishes significantly, and potential risks, such as ovarian hyperstimulation and visual disturbances, may increase. Careful monitoring for ovarian response and potential adverse effects is crucial throughout treatment. |
Safety & Warnings
Common Side Effects
- Clomiphene therapy can be associated with various adverse reactions, ranging from mild to potentially severe.
- Common side effects include vasomotor symptoms (hot flashes), affecting approximately 10% of patients, and abdominal discomfort (e.
- g.
- , distension, pain, bloating, nausea, vomiting) reported in about 5.
- 5% of individuals.
- Visual symptoms, such as blurred vision, scotomata, or diplopia, occur in about 1.
- 5% and, though usually transient, may rarely be prolonged or irreversible.
- Ovarian enlargement, while often asymptomatic, can occur in approximately 13% of cycles.
- Other reported effects include headaches, breast tenderness, abnormal uterine bleeding, weight gain, and mood swings.
- A significant, albeit less common, risk is Ovarian Hyperstimulation Syndrome (OHSS), which can manifest as sudden abdominal distension, severe pain, ascites, pleural effusion, and electrolyte imbalance, requiring immediate medical attention.
- The incidence of multiple pregnancies, primarily twins, is also increased to approximately 5-10%.
- Patients should be counseled on these potential effects and instructed to report any severe or persistent symptoms promptly.
Serious Warnings
- Black Box Warning: Clomiphene (e.g., Ovafin 50mg) does not carry a formal FDA Black Box Warning. However, clinicians and patients must be aware of several **Serious Warnings** associated with its use, necessitating careful patient selection, monitoring, and counseling due to significant potential risks. These serious warnings include: 1. **Ovarian Hyperstimulation Syndrome (OHSS):** Clomiphene treatment can lead to OHSS, a potentially life-threatening medical emergency. OHSS can manifest as rapid ovarian enlargement, severe abdominal pain and distension, nausea, vomiting, diarrhea, ascites, hydrothorax, oliguria, hypovolemia, hemoconcentration, electrolyte imbalance, and thromboembolic events. Patients should be thoroughly informed about the symptoms of OHSS and instructed to report them immediately to their healthcare provider. If signs of OHSS develop, treatment should be discontinued, and the patient must receive immediate and appropriate medical management. 2. **Multiple Pregnancies:** The incidence of multiple gestations, predominantly twin pregnancies (approximately 5-10%) and triplets or more (<1%), is significantly increased with clomiphene therapy compared to natural conception. Multiple pregnancies carry inherent and increased risks for both the mother (e.g., gestational hypertension, preeclampsia, gestational diabetes, preterm labor, postpartum hemorrhage) and the fetuses (e.g., prematurity, low birth weight, congenital anomalies, increased perinatal morbidity and mortality). Patients must be thoroughly counseled on these elevated risks associated with multiple pregnancies before initiating treatment. 3. **Visual Disturbances:** Patients may experience blurred vision, scotomata (spots or flashes), or other visual symptoms. While these are often transient and reversible, there have been rare reports of prolonged or irreversible visual impairment. Patients experiencing any visual symptoms should discontinue treatment immediately and undergo a complete ophthalmologic examination. 4. **Liver Dysfunction:** Clomiphene is contraindicated in patients with active liver disease or a history of liver dysfunction due to its hepatic metabolism and the potential for hepatotoxicity. Liver function tests should be evaluated before and periodically during treatment if clinically indicated to monitor for any adverse effects. 5. **Adverse Fetal Outcomes:** Although overall data do not conclusively suggest an increased risk of major birth defects with clomiphene use, some epidemiological studies have indicated a potential association between clomiphene use and specific congenital anomalies. However, definitive causality has not been established, and these findings require further investigation. Patients should be advised against using clomiphene if pregnancy is suspected or confirmed.
- Patients receiving clomiphene (e.
- g.
- , Ovafin 50mg) should be monitored carefully due to potential serious risks.
- Ovarian Hyperstimulation Syndrome (OHSS) is a significant concern, varying in severity from mild to life-threatening.
- Symptoms of OHSS, such as abdominal pain, distension, nausea, diarrhea, and weight gain, warrant immediate medical evaluation.
- Patients should be advised to report these symptoms promptly.
- The incidence of multiple pregnancies, predominantly twin gestations, is increased with clomiphene use, carrying associated risks for both mother and fetuses.
- Visual disturbances, including blurred vision or scotomata, can occur; patients experiencing such symptoms should discontinue treatment and undergo ophthalmologic evaluation, as these effects may be irreversible in rare cases.
- Clomiphene should not be used in pregnant women.
- Appropriate diagnostic procedures should be performed to rule out other causes of infertility prior to treatment.
- Liver function should be assessed, and clomiphene is contraindicated in patients with active liver disease or a history of liver dysfunction.
How it Works (Mechanism of Action)
Clomiphene citrate functions as a selective estrogen receptor modulator (SERM) with both estrogenic and anti-estrogenic properties, depending on the target tissue. In the context of inducing ovulation, its primary mechanism involves competitively binding to estrogen receptors in the hypothalamus. This binding prevents endogenous estrogens from signaling to the hypothalamus, leading to an incorrect perception of low estrogen levels. Consequently, the hypothalamus increases its pulsatile release of Gonadotropin-Releasing Hormone (GnRH). Elevated GnRH subsequently stimulates the pituitary gland to release increased amounts of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This surge in FSH and LH promotes the growth and development of ovarian follicles, ultimately leading to maturation of the ovum and, ideally, ovulation. The increase in gonadotropin secretion is critical for follicular recruitment and subsequent steroidogenesis, thereby restoring ovulatory function in anovulatory or oligo-ovulatory women.